XBIO · Xenetic Biosciences, Inc.
Xenetic Biosciences Inc (XBIO)
What's happening
- XBIO is up 5.26% today, trading at $2.00. — Live quote
- Volume today (201) is well below its 3-month average of 68,200. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.45 actual vs. $-0.65 estimated (+31.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-02-01 (6 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $6.8M | $6.2M | $4.8M | $5.8M | $4.8M |
| P/E | -2.64 | -2.44 | -1.88 | -1.76 | -1.27 |
| Price/Sales | 2.21 | 2.06 | 1.69 | 2.30 | 1.98 |
| Price/Book | 1.12 | 0.90 | 1.21 | 1.30 | 0.94 |
| EV/Revenue | 2.21 | 2.06 | 1.69 | 2.30 | 1.98 |
| ROE | -42.56% | -36.80% | -64.16% | -74.21% | -74.34% |
| ROA | -37.09% | -32.35% | -50.09% | -61.69% | -65.77% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 12.0% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-23; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -75.9%. Finnhub fundamentals ↗
- Trailing 52-week price return is -51.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on XBIO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $660.6K | $806.9K | $1.0M | $589.9K | $593.3K | $614.2K | $726.4K | $510.8K |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$971.7K | -$502.1K | -$544.7K | -$724.4K | -$942.4K | -$499.5K | -$1.3M | -$1.3M |
| Net income | -$929.7K | -$456.4K | -$509.9K | -$688.7K | -$903.1K | -$436.7K | -$1.3M | -$1.2M |
| EPS (diluted) | $-0.41 | $-0.20 | $-0.33 | $-0.45 | $-0.59 | $-0.28 | $-0.83 | $-0.78 |
| EPS (basic) | $-0.41 | $-0.20 | $-0.33 | $-0.45 | $-0.59 | $-0.28 | $-0.83 | $-0.78 |
| Operating margin | -$147 | -$62 | -$53 | -$123 | -$159 | -$81 | -$184 | -$248 |
| Net margin | -$141 | -$57 | -$50 | -$117 | -$152 | -$71 | -$175 | -$234 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $7.0M | $7.9M | $8.4M | $5.1M | $5.4M | $5.8M | $6.9M | $8.0M |
| Total liabilities | $895.0K | $958.2K | $968.0K | $1.1M | $903.4K | $667.9K | $894.3K | $1.0M |
| Stockholders' equity | $6.1M | $7.0M | $7.4M | $4.0M | $4.5M | $5.1M | $6.0M | $7.0M |
| Total current assets | $6.7M | $7.6M | $8.0M | $5.1M | $5.4M | $5.5M | $6.6M | $7.0M |
| Total current liabilities | $895.0K | $958.2K | $968.0K | $1.1M | $903.4K | $667.9K | $894.3K | $1.0M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — |
| Other non-current assets | $313.9K | $313.9K | $313.9K | $0 | $0 | $313.9K | $313.9K | $1.0M |
| Accounts payable | $322.5K | $558.8K | $258.1K | $578.2K | $346.8K | $240.3K | $283.6K | $243.3K |
| Accrued liabilities | — | — | $709.9K | — | — | — | $610.6K | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $2.3K | $2.3K | $2.3K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K |
| Retained earnings | -$201.3M | -$200.3M | -$199.9M | -$199.3M | -$198.8M | -$198.1M | -$197.2M | -$196.1M |
| Accumulated other comprehensive income (loss) | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$875.5K | -$536.4K | -$242.7K | -$658.2K | -$383.8K | -$1.0M | -$674.0K | -$459.0K |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | $4.0M | — | — | — | $0 | — |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $52.0K | $11.3K | $45.5K | $15.9K | $15.7K | $19.3K | $94.7K | $27.5K |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M |
| Gross profit | — | — | — | — | — |
| Operating income | -$2.8M | -$4.2M | -$4.5M | -$6.7M | -$5.7M |
| Net income | -$2.7M | -$4.0M | -$4.1M | -$6.6M | -$5.6M |
| EPS (diluted) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 |
| EPS (basic) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 |
| Operating margin | -$95 | -$168 | -$178 | -$394 | -$495 |
| Net margin | -$90 | -$158 | -$163 | -$384 | -$486 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $8.4M | $6.9M | $10.6M | $14.7M | $19.8M |
| Total liabilities | $968.0K | $894.3K | $809.6K | $1.1M | $1.4M |
| Stockholders' equity | $7.4M | $6.0M | $9.8M | $13.6M | $18.4M |
| Total current assets | $8.0M | $6.6M | $9.6M | $13.7M | $18.7M |
| Total current liabilities | $968.0K | $894.3K | $809.6K | $1.1M | $1.4M |
| Accounts receivable | — | — | — | — | — |
| Property, plant & equipment | — | — | — | $0 | $0 |
| Goodwill | — | — | — | — | — |
| Other non-current assets | $313.9K | $313.9K | $1.0M | $1.1M | $1.1M |
| Accounts payable | $258.1K | $283.6K | $240.8K | $287.4K | $362.5K |
| Accrued liabilities | $709.9K | $610.6K | $568.8K | $785.8K | $1.0M |
| Other current liabilities | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $2.3K | $1.5K | $1.5K | $1.5K | $13.5K |
| Retained earnings | -$199.9M | -$197.2M | -$193.2M | -$189.1M | -$182.5M |
| Accumulated other comprehensive income (loss) | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$2.3M | -$2.8M | -$4.1M | -$4.6M | -$4.7M |
| Investing cash flow | — | — | $0 | -$500.0K | $0 |
| Financing cash flow | $4.0M | $0 | — | $0 | $11.5M |
| Capital expenditures | — | — | — | — | — |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $64.8K | $171.8K | $283.1K | $511.5K | $410.4K |
| Change in accounts receivable | — | — | — | — | — |
| Change in accounts payable | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding XBIO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-21 to 2026-04-21
Recent transactions
- Most recent: PARSLOW JAMES F (Interim CEO and CFO) — Grant / award of 100,000 shares on 2026-04-21.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| PARSLOW JAMES F | Interim CEO and CFO | Grant / award | 2026-04-21 | 100,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-04-21 | PARSLOW JAMES F | Interim CEO and CFO | Grant / award | 100,000 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:53 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-23 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-09-16 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-08-07 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-05-13 | 8-K | 2026-05-13 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-04-24 | 8-K | 2026-04-21 | View on SEC.gov → |
| 2026-04-23 | 4 | 2026-04-21 | View on SEC.gov → |
| 2026-03-13 | 8-K | 2026-03-13 | View on SEC.gov → |
| 2026-03-12 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-01-09 | 8-K | 2026-01-08 | View on SEC.gov → |
| 2026-01-05 | 4 | 2025-12-31 | View on SEC.gov → |
Recent news
Headlines about XBIO (Xenetic Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymp
Yahoo · 2026-10-15 -
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
Yahoo Finance · 2026-10-15 -
Xenetic Biosciences Announces Its Collaboration Partner PeriNess Doses First Participant In Clinical Trial Of Systemic Recombinant Human DNase To Treat Large B-Cell Lymphoma In Israel
Benzinga · 2026-10-15 -
Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript
Seeking Alpha · 2026-09-16 -
Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake
Yahoo Finance · 2026-09-16 -
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition
Yahoo Finance · 2026-09-16 -
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Yahoo Finance · 2026-09-16 -
Xenetic Biosciences reports Q2 results
Seeking Alpha · 2026-08-07
No headlines in this category right now — try “All”.